CapseraSGLT2 inhibitors
Compare the named medicines in this source-linked class directory.
Membership describes a named action or a component of a combination. A medicine may appear in several families. Medicines in one family are not automatically interchangeable; this is a study directory, not a prescribing guide.
No matching drugs. Try another name.
Generic names and pronunciation
Shared name ending: -gliflozin · Empagliflozin, Dapagliflozin
| Empagliflozin · em-pa-gli-FLOE-zin |
| Dapagliflozin · dap-a-gli-FLOE-zin |
Pronunciation is shown for the US English generic name. A name ending is a memory cue, not a classification rule.
Body system and related classes
Body system: Endocrine
How each medicine works
| Empagliflozin — Inhibits renal SGLT2, reducing glucose reabsorption and increasing urinary glucose excretion; also reduces sodium reabsorption and increases sodium delivery to the distal tubule. |
| Dapagliflozin — Inhibits SGLT2 in the proximal renal tubule, reducing filtered glucose reabsorption and increasing urinary glucose excretion. |
Each summary is the mechanism line from the medicine’s study card.
What each medicine is used for
| Empagliflozin — Adjunct to diet and exercise for glycemic control in adults and children aged 10 years and older with type 2 diabetes; not recommended for this use when eGFR is below 30 mL/min/1.73 m²; Reduction of cardiovascular death and heart-failure hospitalization in adults with heart failure; Reduction of kidney decline, end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease at risk of progression; the label excludes specified polycystic and immunosuppression-treated kidney-disease populations from recommended use; Reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease |
| Dapagliflozin — Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; this use is not recommended when eGFR is below 45 mL/min/1.73 m²; Reduction of heart-failure hospitalization in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors |
Each list is the uses line from the medicine’s study card.
Telling these medicines apart
Medicines in this class: 2
Listed on more than one card in this class
Common side effects
Urinary tract infections · 2/2: Empagliflozin, Dapagliflozin
Female genital mycotic infections · 2/2: Empagliflozin, Dapagliflozin
Warnings
Ketoacidosis · 2/2: Empagliflozin, Dapagliflozin
Volume depletion · 2/2: Empagliflozin, Dapagliflozin
Interactions
Insulin or insulin secretagogues · 2/2: Empagliflozin, Dapagliflozin
Lithium · 2/2: Empagliflozin, Dapagliflozin
Listed on only one card in this class
Empagliflozin: Warnings — Genitourinary infections incl. Fournier's gangrene · Interactions — Diuretics
Dapagliflozin: Common side effects — Nasopharyngitis · Warnings — Genitourinary infections / Fournier's gangrene
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.